GST-HG161

GST-HG161 is a potent, highly selective, and orally bioavailable small molecule inhibitor of the c-MET (Hepatocyte Growth Factor Receptor) tyrosine kinase. Developed by Fujian Guosheng Pharmaceutical, it targets the c-MET signaling pathway, which is frequently dysregulated in various cancers through gene amplification, overexpression, or mutations (such as MET exon 14 skipping). By binding to the kinase domain of c-MET, GST-HG161 inhibits its phosphorylation and subsequent activation of downstream signaling cascades, including the PI3K/AKT, RAS/MAPK, and STAT3 pathways, thereby suppressing tumor cell proliferation, migration, and survival. The compound is currently undergoing Phase I clinical evaluation in patients with advanced or metastatic solid tumors that are c-MET positive.

Other names

gemnelatinib